William Ball, senior equity analyst at Sanlam Private Wealth, analyses the US's troubled healthcare system and the changes a new president could implement in the sector, which has been at the 'heart' of the election campaigns.
Drug pricing has certainly become an emotionally charged topic during the past few months. Healthcare stocks have broadly sold off since the end of July, in part down to investors rotating out of defensive equities. Hillary Clinton (pictured) condemned the "outrageous" and "price-gouging" practices of embattled manufacturer Mylan (which has hiked the price of its decade old anti-parasitic drug EpiPen by roughly 400% since 2008), and has called for an end to "unjustified price increases not for new innovations, but for long-available and generic treatments". Earlier this month, Clinton...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes